Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPNT message board posts where the ticker symbol OPNT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPNT SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-13-002597 (34 Act)  Size: 46 KB
2013-02-11 005-60291
13589481
15-12G  Documents Securities registration termination [Section 12(g)]
Acc-no: 0001193125-12-518791 (34 Act)  Size: 11 KB
2012-12-31 000-30931
121292416
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-12-069989 (34 Act)  Size: 42 KB
2012-12-28 005-60291
121290185
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-12-069987 (34 Act)  Size: 42 KB
2012-12-28 005-60291
121290178
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001193125-12-510792 (34 Act)  Size: 78 KB
2012-12-21 005-60291
121278392
SC TO-T/A  Documents [Amend] Tender offer statement by Third Party
Acc-no: 0001193125-12-510792 (34 Act)  Size: 78 KB
2012-12-21 005-60291
121278391
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058920 Size: 7 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058763 Size: 15 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058762 Size: 7 KB
2012-12-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-12-058761 Size: 8 KB
2012-12-20
More OPNT SEC Filings


Related news from
Tue, 15 May 2018
14:35:00 +0000
OPNT: KOL Event Highlights Medications for Addictions and Related Disorders
Dr. Comer is a Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons at Columbia University. Dr. Comer began her talk with an overview of the epidemiology of the opioid epidemic. The following graphic shows the startling increase in drug overdose deaths from 1999 to 2016.
Tue, 08 May 2018
20:05:00 +0000
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 08, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first ...
Thu, 03 May 2018
12:00:00 +0000
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, will host a Key Opinion Leader (KOL) luncheon on Medications for Addictions and Related Disorders on Thursday, May 10 in New York City. The event will feature presentations by KOLs Sandra Comer, PhD, Columbia University, Susan McElroy, MD, University of Cincinnati, and Stephanie O'Malley, PhD, Yale School of Medicine, who will discuss the current treatment landscape and unmet medical need for treating patients with substance use and eating disorders.
Fri, 20 Apr 2018
11:30:00 +0000
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT) ("Opiant"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPNT as the Company's latest news hit the wire. On April 18, 2018, the Company, which is a specialty pharmaceutical organization developing pharmacological treatments for addictions, declared that the National Institutes of Health's National Institute on Drug Abuse (NIDA) has granted it an award of approximately $7.4 million for the development of OPNT003 (intranasal nalmefene) for opioid overdose.
Wed, 18 Apr 2018
12:00:00 +0000
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. “We view this NIDA grant as further validation of the potential for OPNT003 to be an important treatment for opioid overdose, a growing U.S. health epidemic,” said Roger Crystal, M.D., Chief Executive Officer of Opiant.  “Fentanyl was responsible for more overdose deaths (in excess of 20,000) than either heroin or prescription opioids in 2016.  Recognizing the evolution of the opioid crisis, the National Institutes of Health has called for the development of stronger, longer-acting overdose reversal products in order to address this next wave of potent synthetic opioids, like fentanyl.
Tue, 03 Apr 2018
12:00:00 +0000
Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, April 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Thu, 22 Mar 2018
11:00:00 +0000
Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates
Stock Monitor: Opiant Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free earnings report on HubSpot, Inc. (NYSE: HUBS ). If you want ...
Wed, 21 Mar 2018
14:45:00 +0000
OPNT: Opiant Developing New Opioid Overdose Treatment
As part of the solution to the problem, the CDC recommends that the federal government “improve access to…overdose-reversing drugs, such as naloxone” and that health departments “increase naloxone distribution to first responders, family and friends, and other community members in affected areas” (CDC). While not a treatment for opioid dependence, health authorities believe that easy access to naloxone is an essential component of battling the ongoing opioid crisis due to its effectiveness in preventing overdose deaths. On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment.
Mon, 19 Mar 2018
21:54:25 +0000
Trump says he is working to lower prescription drug prices
President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. "If you compare our drug prices to other countries in the world, in some cases it's many times higher for the exact same pill or whatever it is, in the exact same package made in the exact same plant," Trump said. Trump made the remarks during a speech in Manchester, New Hampshire that focused on the administration's efforts to battle the nation's opioid addiction crisis.
Mon, 19 Mar 2018
21:04:50 +0000
As U.S. opioid crisis grows, Trump calls for death penalty for dealers
President Donald Trump spelled out in new detail several steps he favors to fight a U.S. epidemic of opioid abuse, including the execution of drug dealers, a proposal that has gained little support from drug abuse and judicial experts. At an event in Manchester, New Hampshire, Trump unveiled an anti-opioid abuse plan, including his death penalty recommendation, new funding for other initiatives and stiffer sentencing laws for drug dealers.
Mon, 19 Mar 2018
20:05:00 +0000
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
SANTA MONICA, Calif., March 19, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President ...
Wed, 07 Mar 2018
21:05:00 +0000
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
SANTA MONICA, Calif., March 07, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, following the recent approval by its Board ...
Thu, 22 Feb 2018
13:00:00 +0000
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
SAN DIEGO, Feb. 22, 2018-- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple opioid blockers such ...
Tue, 13 Feb 2018
17:00:00 +0000
OPNT: Developing Longer-Acting Opioid Overdose Treatment
On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT003 is an intranasal formulation of nalmefene, a naltrexone derivative. The U.S. continues to battle an opioid epidemic.
Sun, 31 Dec 2017
18:45:23 +0000
Insider Q&A: Narcan exec talks merits of spray for overdoses
Dr. Roger Crystal's company was struggling to find new uses for an old drug that reverses overdoses. Then the opioid epidemic hit. Naloxone had first gone on sale in 1971 but was injected with a syringe. ...
Wed, 20 Dec 2017
19:30:00 +0000
OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18
On December 20, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced that it expects to begin receiving 90% of royalty and milestone payments related to the sale of NARCAN® Nasal Spray beginning in the first quarter of 2018. On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones were met.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is an awesome community of bright, serious, passionate and involved individual investors. Information is well organized into fine-grained topics and discussions are always on topic and relevant. People here certainly know what value is and this site itself is a great reflection of that. I feel honored and privileged to have found such a great resource and to be part of it!" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards